Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses

Fig. 2

Kaplan–Meier curves for progression-free survival for axitinib versus everolimus: (a) base-case analysis; (b) sensitivity analysis. aHR, adjusted hazard ratio; CI, confidence interval; ESS, effective sample size; MAIC, matching-adjusted indirect treatment comparison; PFS, progression-free survival

Back to article page